Generic Version Of Remdesivir
- All
- News
- Videos
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
